Phase 3 Myeloma Trial, RecruitingNCT05243797Sponsor: European Myeloma Network B.V.Condition: Myeloma
Printed from Voxsanity (voxsanity.com.au) — NCT05243797 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.
AI generated eligibility summary.
Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source.
How we use AI
Who might be able to join this trial:
People who have been newly diagnosed with multiple myeloma (according to standard international diagnostic guidelines) and have already completed an initial course of treatment, which may or may not have included a consolidation phase.
People who have received only one course of treatment for their multiple myeloma and whose disease responded at least partially to that treatment, with no signs of the disease getting worse by the time the trial starts.
People who were able to tolerate the standard starting dose of a drug called lenalidomide.
People who have not yet received any ongoing maintenance treatment for their multiple myeloma.
People whose general physical health and ability to carry out daily activities falls within an acceptable range at the screening stage (rated 0, 1, or 2 on a standard medical scale).
People whose blood and other lab test results fall within the ranges required by the trial.
Who may not be able to join:
People who have previously received any treatment that specifically targets a protein called BCMA.
People who have previously received a type of therapy that redirects immune cells, or any gene-modified cell therapy (for example, treatments using modified T cells or NK cells).
People who had to stop taking lenalidomide in the past because of a side effect from that drug.
People whose multiple myeloma got worse at any point during previous treatment.
People who received a high cumulative dose of steroid medications (equivalent to 140 mg or more of prednisone) in the 14 days before the trial treatment would begin.
People who received a live or live-attenuated vaccine within the 4 weeks before the trial treatment would begin (non-live vaccines and non-replicating vaccines, such as certain COVID-19 vaccines, are generally permitted — confirm with trial site).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 6 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.
Contact this trial
Principal Investigator: Niels van de Donk, Professor, Amsterdam UMC, Vrije Universiteit Amsterdam
Barwon Health University Hospital Geelong Andrew Love Cancer Centre, Geelong,
Alfred Hospital, Melbourne,
Austin Health, Melbourne,
Calvary Mater Hospital, Newcastle,
Concord Repatriation General Hospital, Sydney,
Royal North Shore Hospital, Sydney,
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Voxsanity
Clinical trials and treatments, explained plainly · voxsanity.com.au
Date:
To: My Doctor
Re: Clinical trial enquiry
I am writing to enquire about the following clinical trial which may be relevant to my care:
Trial: NCT05243797
Sponsor: European Myeloma Network B.V.
Phase: Phase 3
Status: Recruiting
Condition: Myeloma
Trial contact: +31 10 268 70 65
More information: https://clinicaltrials.gov/study/NCT05243797
Eligibility summary (AI generated)
Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.
Who might be able to join this trial:
People who have been newly diagnosed with multiple myeloma (according to standard international diagnostic guidelines) and have already completed an initial course of treatment, which may or may not have included a consolidation phase.
People who have received only one course of treatment for their multiple myeloma and whose disease responded at least partially to that treatment, with no signs of the disease getting worse by the time the trial starts.
People who were able to tolerate the standard starting dose of a drug called lenalidomide.
People who have not yet received any ongoing maintenance treatment for their multiple myeloma.
People whose general physical health and ability to carry out daily activities falls within an acceptable range at the screening stage (rated 0, 1, or 2 on a standard medical scale).
People whose blood and other lab test results fall within the ranges required by the trial.
Who may not be able to join:
People who have previously received any treatment that specifically targets a protein called BCMA.
People who have previously received a type of therapy that redirects immune cells, or any gene-modified cell therapy (for example, treatments using modified T cells or NK cells).
People who had to stop taking lenalidomide in the past because of a side effect from that drug.
People whose multiple myeloma got worse at any point during previous treatment.
People who received a high cumulative dose of steroid medications (equivalent to 140 mg or more of prednisone) in the 14 days before the trial treatment would begin.
People who received a live or live-attenuated vaccine within the 4 weeks before the trial treatment would begin (non-live vaccines and non-replicating vaccines, such as certain COVID-19 vaccines, are generally permitted — confirm with trial site).
Important: Always verify eligibility with the trial site directly before applying.
Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.
This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 6 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.
Trial details
Status
Recruiting
Phase
Phase 3
Sponsor
European Myeloma Network B.V.
Registry
ClinicalTrials.gov
Start date
8 September 2022
Est. completion
1 April 2028
Where this trial is recruiting
🇦🇷 Argentina
🇦🇺 Australia
🇦🇹 Austria
🇧🇪 Belgium
🇧🇷 Brazil
🇨🇦 Canada
🇨🇳 China
🇨🇿 Czechia
🇩🇰 Denmark
🇫🇷 France
🇩🇪 Germany
🇬🇷 Greece
🇮🇪 Ireland
🇮🇱 Israel
🇮🇹 Italy
🇳🇱 Netherlands
🇳🇴 Norway
🇵🇱 Poland
🇵🇹 Portugal
🇷🇸 Serbia
🇰🇷 South Korea
🇨🇭 Switzerland
Turkey (Türkiye)
🇬🇧 United Kingdom
🇺🇸 United States
9 site(s) in Australia. Confirm current status and contact details directly with the trial site.
If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.
Data last synced from ClinicalTrials.gov: 6 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.
Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.